Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations.

Introduction: Cannabidiol (CBD) is the second most abundant Phytocannabinoid in Cannabis extracts. CBD has a binding affinity for several cannabinoid and cannabinoid-associated receptors. Epidiolex (oral CBD solution) has been lately licensed by the Food and Drug Administration (FDA) for the treatment of pediatric epileptic seizures. Methods: In this review, we discussed the most promising applications of CBD for chronic inflammatory conditions, namely CBD's anti-inflammatory effects during inflammatory bowel disease, coronavirus disease (antiviral effect), brain pathologies (neuroprotective and anti-inflammatory properties), as well as CBD immunomodulatory and antitumoral activities in the tumor microenvironment. Special focus was shed on the main therapeutic mechanisms of action of CBD, particularly in the control of the immune system and the endocannabinoid system. Results: Findings suggest that CBD is a potent immunomodulatory drug as it has manifested immunosuppressive properties in the context of sterile inflammation (e.g., inflammatory bowel disease, rheumatoid arthritis, and neurodegenerative diseases), and immunoprotective effects during viral infections (e.g. COVID-19) Similarly, CBD has exhibited a selective response toward cancer types by engaging different targets and signaling pathways. These results are in favor of the primary function of the endocannabinoid system which is homeostatic maintenance. Conclusion: The presented evidence suggests that the endocannabinoid system is a prominent target for the treatment of inflammatory and autoimmune diseases, rheumatoid diseases, viral infections, neurological and psychological pathologies, and cancer. Moreover, the antitumoral activities of CBD have been suggested to be potentially used in combination with chemo- or immunotherapy during cancer. However, clinical results are still lacking, which raises a challenge to apply translational cannabis research to the human immune system.

[1]  Shengyu Li,et al.  Cannabidiol Alleviates the Damage to Dopaminergic Neurons in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson’s Disease Mice Via Regulating Neuronal Apoptosis and Neuroinflammation , 2022, Neuroscience.

[2]  C. Bréchot,et al.  A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19 , 2022, eClinicalMedicine.

[3]  N. Flamand,et al.  Expression and Functions of the CB2 Receptor in Human Leukocytes , 2022, Frontiers in Pharmacology.

[4]  K. O’Brien.  Cannabidiol (CBD) in Cancer Management , 2022, Cancers.

[5]  D. Meltzer,et al.  Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. , 2022, Science advances.

[6]  Jack C. Yu,et al.  Inhalant Cannabidiol Inhibits Glioblastoma Progression Through Regulation of Tumor Microenvironment. , 2021, Cannabis and cannabinoid research.

[7]  Bo Ram Kim,et al.  Cannabidiol Suppresses Angiogenesis and Stemness of Breast Cancer Cells by Downregulation of Hypoxia-Inducible Factors-1α , 2021, Cancers.

[8]  R. Crawford,et al.  Cannabidiol selectively modulates interleukin (IL)-1β and IL-6 production in toll-like receptor activated human peripheral blood monocytes. , 2021, Toxicology.

[9]  Yinyi Xiong,et al.  Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease , 2021, Brain sciences.

[10]  N. Toyang,et al.  The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases , 2021, International journal of molecular sciences.

[11]  M. Caron,et al.  Biased Coupling to β-Arrestin of Two Common Variants of the CB2 Cannabinoid Receptor , 2021, Frontiers in Endocrinology.

[12]  D. Zylla,et al.  Cannabis as an Anticancer Agent: A Review of Clinical Data and Assessment of Case Reports. , 2021, Cannabis and cannabinoid research.

[13]  T. Piva,et al.  The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer , 2021, Cancers.

[14]  A. Sadanandam,et al.  Cannabinoids in the landscape of cancer , 2021, Journal of Cancer Research and Clinical Oncology.

[15]  C. Limebeer,et al.  Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting. , 2021, Cannabis and cannabinoid research.

[16]  C. Page,et al.  The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. , 2021, Pulmonary pharmacology & therapeutics.

[17]  C. Lim,et al.  The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo Studies. , 2021, Cannabis and cannabinoid research.

[18]  M. Hassan,et al.  The Molecular targets of Cannabinoids in the treatment of Cancer and Inflammation. , 2021, Current pharmaceutical design.

[19]  E. Souto,et al.  Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action , 2021, International journal of molecular sciences.

[20]  C. Laezza,et al.  Molecular Mechanism of Cannabinoids in Cancer Progression , 2021, International journal of molecular sciences.

[21]  C. Helmstaedter,et al.  Cannabidiol in the Treatment of Epilepsy , 2021, Clinical Drug Investigation.

[22]  M. Cosentino,et al.  Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review , 2021, Journal of Neuroimmune Pharmacology.

[23]  Sahar S. Abd El-Rahman,et al.  Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by Cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide. , 2021, Chemico-biological interactions.

[24]  A. C. Vinayaka,et al.  Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages , 2021, Scientific reports.

[25]  N. Salomonis,et al.  Cannabidiol Treatment Results in a Common Gene Expression Response Across Aggressive Cancer Cells from Various Origins. , 2020, Cannabis and cannabinoid research.

[26]  Do Yeon Kim,et al.  Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma , 2020, Scientific Reports.

[27]  L. Devi,et al.  Diversity of molecular targets and signaling pathways for CBD , 2020, Pharmacology research & perspectives.

[28]  J. Mlost,et al.  Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action , 2020, International journal of molecular sciences.

[29]  J. Manzanares,et al.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders , 2020, Biomolecules.

[30]  Dong Zhang,et al.  Cannabidiol (CBD) as a Promising Anti-Cancer Drug , 2020, Cancers.

[31]  S. Vlachou,et al.  A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment , 2020, Molecules.

[32]  Fengjin Hao,et al.  Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer's mice uncovered by RNA-seq. , 2020, Life sciences.

[33]  Aleksandra Kicman,et al.  The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease , 2020, International journal of molecular sciences.

[34]  Yunman Li,et al.  The role of Th17 cells in psoriasis , 2020, Immunologic Research.

[35]  Matthias Schneider,et al.  Cannabidiol (CBD): a killer for inflammatory rheumatoid arthritis synovial fibroblasts , 2020, Cell Death & Disease.

[36]  Zhi-jie Liu,et al.  Structural and Functional Insights into Cannabinoid Receptors. , 2020, Trends in pharmacological sciences.

[37]  P. Xiao,et al.  Structural basis of signaling of cannabinoids receptors: paving a way for rational drug design in controling mutiple neurological and immune diseases , 2020, Signal Transduction and Targeted Therapy.

[38]  P. Kubatka,et al.  Calcium Entry through TRPV1: A Potential Target for the Regulation of Proliferation and Apoptosis in Cancerous and Healthy Cells , 2020, International journal of molecular sciences.

[39]  N. Irrera,et al.  β-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors , 2020, Biomedicines.

[40]  Barbara L F Kaplan,et al.  CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN-γ + CD8+ T Cells and Modest Inhibition of Neuroinflammation , 2020, Journal of Neuroimmune Pharmacology.

[41]  K. Kuča,et al.  Cannabis Constituents and Acetylcholinesterase Interaction: Molecular Docking, In Vitro Studies and Association with CNR1 rs806368 and ACHE rs17228602 , 2020, Biomolecules.

[42]  F. Vale,et al.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies , 2020, EPMA Journal.

[43]  Matthew D. Dun,et al.  Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer , 2020, Cancers.

[44]  C. Rubira,et al.  Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse , 2020, International journal of molecular sciences.

[45]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[46]  A. Gęgotek,et al.  Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris , 2020, Biomolecules.

[47]  Barbara L F Kaplan,et al.  Immune Responses Regulated by Cannabidiol , 2020, Cannabis and cannabinoid research.

[48]  D. Calina,et al.  Cannabinoids in the Pathophysiology of Skin Inflammation , 2020, Molecules.

[49]  S. Atalay,et al.  Antioxidative and Anti-Inflammatory Properties of Cannabidiol , 2019, Antioxidants.

[50]  T. Bisogno,et al.  Cannabinoids and the expanded endocannabinoid system in neurological disorders , 2019, Nature Reviews Neurology.

[51]  I. Rahman,et al.  Cannabidiol differentially regulates basal and LPS-induced inflammatory responses in macrophages, lung epithelial cells, and fibroblasts. , 2019, Toxicology and applied pharmacology.

[52]  A. Hernández-Cruz,et al.  Cannabidiol directly targets mitochondria and disturbs calcium homeostasis in acute lymphoblastic leukemia , 2019, Cell Death & Disease.

[53]  C. Stove,et al.  Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. , 2019, Biochemical pharmacology.

[54]  A. Burggren,et al.  Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives , 2019, The American journal of drug and alcohol abuse.

[55]  Lingyan Ye,et al.  New Insights in Cannabinoid Receptor Structure and Signaling. , 2019, Current molecular pharmacology.

[56]  T. England,et al.  A systematic review of cannabidiol dosing in clinical populations , 2019, British journal of clinical pharmacology.

[57]  C. White,et al.  A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential , 2019, Journal of clinical pharmacology.

[58]  M. Novotny,et al.  Beta-caryophyllene enhances wound healing through multiple routes , 2019, bioRxiv.

[59]  C. González-Espinosa,et al.  TLR4 Receptor Induces 2-AG–Dependent Tolerance to Lipopolysaccharide and Trafficking of CB2 Receptor in Mast Cells , 2019, The Journal of Immunology.

[60]  M. Glass,et al.  Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence , 2019, Front. Pharmacol..

[61]  Jack C. Yu,et al.  Cannabinoids as a Potential New and Novel Treatment for Melanoma: A Pilot Study in a Murine Model. , 2019, The Journal of surgical research.

[62]  P. Morales,et al.  Cannabinoid Ligands Targeting TRP Channels , 2019, Front. Mol. Neurosci..

[63]  F. Dal-Pizzol,et al.  Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma , 2019, European journal of pharmacology.

[64]  Ron O. Dror,et al.  Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex , 2019, Cell.

[65]  G. Bar-Sela,et al.  Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology , 2018, Expert opinion on investigational drugs.

[66]  A. Simmons,et al.  Cannabis, Cannabinoids, and the Endocannabinoid System—Is there Therapeutic Potential for Inflammatory Bowel Disease? , 2018, Journal of Crohn's & colitis.

[67]  M. García-Arencibia,et al.  Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells , 2018, British journal of pharmacology.

[68]  B. Gidal,et al.  A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects , 2018, CNS Drugs.

[69]  A. Sultan,et al.  Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. , 2018, Breast.

[70]  M. Nazıroğlu,et al.  Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model , 2018, Molecular and Cellular Biochemistry.

[71]  M. Nagarkatti,et al.  Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells , 2018, Front. Immunol..

[72]  Y. Shoenfeld,et al.  Cannabinoids for the treatment of rheumatic diseases — where do we stand? , 2018, Nature Reviews Rheumatology.

[73]  U. Kumar,et al.  Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System , 2018, International journal of molecular sciences.

[74]  S. Steffens,et al.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly , 2018, Nature Reviews Cardiology.

[75]  M. Coronado,et al.  Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis , 2017, Experimental Neurology.

[76]  T. Bíró,et al.  Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges , 2017, Front. Immunol..

[77]  R. Guillevin,et al.  Effects of cannabidiol interactions with Wnt/&bgr;-catenin pathway and PPAR&ggr; on oxidative stress and neuroinflammation in Alzheimer's disease , 2017, Acta biochimica et biophysica Sinica.

[78]  Gabriel E. Mateo-Semidey,et al.  Retromer stops beta-arrestin 1–mediated signaling from internalized cannabinoid 2 receptors , 2017, Molecular biology of the cell.

[79]  A. Malfitano,et al.  Cannabidiol: State of the art and new challenges for therapeutic applications. , 2017, Pharmacology & therapeutics.

[80]  T. Hei,et al.  Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways , 2017, Oncotarget.

[81]  S. Basu,et al.  Endocannabinoid system acts as a regulator of immune homeostasis in the gut , 2017, Proceedings of the National Academy of Sciences.

[82]  G. Gabay,et al.  Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial , 2017, Digestive Diseases and Sciences.

[83]  A. Makriyannis,et al.  Functional selectivity at G‐protein coupled receptors: Advancing cannabinoid receptors as drug targets , 2017, Biochemical pharmacology.

[84]  Ethan B. Russo.  Cannabidiol Claims and Misconceptions. , 2017, Trends in pharmacological sciences.

[85]  T. Karl,et al.  In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease , 2017, Front. Pharmacol..

[86]  V. Lelong-Boulouard,et al.  Focus on cannabinoids and synthetic cannabinoids , 2017, Clinical pharmacology and therapeutics.

[87]  Barbara L F Kaplan,et al.  Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. , 2017, Cellular immunology.

[88]  N. Solowij,et al.  A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia , 2017, Neuroscience & Biobehavioral Reviews.

[89]  T. Bíró,et al.  Targeting Cutaneous Cannabinoid Signaling in Inflammation - A “High”-way to Heal? , 2017, EBioMedicine.

[90]  H. de Vries,et al.  Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity , 2017, Nature Communications.

[91]  R. Levy,et al.  β-Caryophyllene promotes osteoblastic mineralization, and suppresses osteoclastogenesis and adipogenesis in mouse bone marrow cultures in vitro , 2016, Experimental and therapeutic medicine.

[92]  D. Deutsch.  A Personal Retrospective: Elevating Anandamide (AEA) by Targeting Fatty Acid Amide Hydrolase (FAAH) and the Fatty Acid Binding Proteins (FABPs) , 2016, Front. Pharmacol..

[93]  N. Flamand,et al.  The CB2 receptor and its role as a regulator of inflammation , 2016, Cellular and Molecular Life Sciences.

[94]  U. Jäger,et al.  Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation , 2016, PloS one.

[95]  K. Mackie,et al.  An Introduction to the Endogenous Cannabinoid System , 2016, Biological Psychiatry.

[96]  A. Weller,et al.  Prohedonic Effect of Cannabidiol in a Rat Model of Depression , 2016, Neuropsychobiology.

[97]  D. Abrams,et al.  Integrating cannabis into clinical cancer care. , 2016, Current oncology.

[98]  G. Velasco,et al.  Anticancer mechanisms of cannabinoids. , 2016, Current oncology.

[99]  Corey Tsang,et al.  Nabilone for the Management of Pain , 2016, Pharmacotherapy.

[100]  C. Fiocchi,et al.  Immunopathogenesis of IBD: current state of the art , 2016, Nature Reviews Gastroenterology &Hepatology.

[101]  W. Häuser,et al.  Wirksamkeit, Verträglichkeit und Sicherheit von Cannabinoiden in der Gastroenterologie , 2016, Der Schmerz.

[102]  R. Laprairie,et al.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor , 2015, British journal of pharmacology.

[103]  Vincenzo Di Marzo,et al.  The Endocannabinoid System and its Modulation by Phytocannabinoids , 2015, Neurotherapeutics.

[104]  K. Shilo,et al.  Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti‐tumor mechanisms of Cannabidiol in breast cancer , 2015, Molecular oncology.

[105]  A. Malfitano,et al.  What we know and do not know about the cannabinoid receptor 2 (CB2). , 2014, Seminars in immunology.

[106]  J. Zajicek,et al.  Pharmacology: Cannabis in neurology—a potted review , 2014, Nature Reviews Neurology.

[107]  Benjamin J. Whalley,et al.  Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders , 2014, Epilepsia.

[108]  M. Boks,et al.  Cannabidiol as a potential treatment for psychosis , 2014, European Neuropsychopharmacology.

[109]  M. Hansmann,et al.  Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma , 2013, PloS one.

[110]  I. Dotan,et al.  Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[111]  Z. Vogel,et al.  Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype , 2013, Journal of Neuroimmune Pharmacology.

[112]  C. Laezza,et al.  The endocannabinoid signaling system in cancer. , 2013, Trends in pharmacological sciences.

[113]  R. Cuomo,et al.  Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview , 2013, Phytotherapy research : PTR.

[114]  Barbara L F Kaplan,et al.  The role of CB1 in immune modulation by cannabinoids. , 2013, Pharmacology & therapeutics.

[115]  B. Molnár,et al.  Changes of the cytokine profile in inflammatory bowel diseases. , 2012, World journal of gastroenterology.

[116]  A. Albini,et al.  Cannabidiol inhibits angiogenesis by multiple mechanisms , 2012, British journal of pharmacology.

[117]  V. Cinquina,et al.  Cannabidiol administration after hypoxia–ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function , 2012, Neuropharmacology.

[118]  Z. Atakan.  Cannabis, a complex plant: different compounds and different effects on individuals , 2012, Therapeutic advances in psychopharmacology.

[119]  R. Reimer,et al.  Cannabinoid signalling regulates inflammation and energy balance: The importance of the brain–gut axis , 2012, Brain, Behavior, and Immunity.

[120]  G. Velasco,et al.  Towards the use of cannabinoids as antitumour agents , 2012, Nature Reviews Cancer.

[121]  Peter T. Nguyen,et al.  β-Arrestin2 Regulates Cannabinoid CB1 Receptor Signaling and Adaptation in a Central Nervous System Region–Dependent Manner , 2012, Biological Psychiatry.

[122]  M. Storr,et al.  Topical and Systemic Cannabidiol Improves Trinitrobenzene Sulfonic Acid Colitis in Mice , 2012, Pharmacology.

[123]  E. Williamson,et al.  Cannabinoids in Clinical Practice , 2000, Drugs.

[124]  L. Steardo,et al.  Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement , 2011, PloS one.

[125]  L. Marnett,et al.  Cannabinoids, endocannabinoids, and cancer , 2011, Cancer and Metastasis Reviews.

[126]  Åke Öberg,et al.  High Tumour Cannabinoid CB1 Receptor Immunoreactivity Negatively Impacts Disease-Specific Survival in Stage II Microsatellite Stable Colorectal Cancer , 2011, PloS one.

[127]  Patrice D Cani,et al.  Increasing endogenous 2‐arachidonoylglycerol levels counteracts colitis and related systemic inflammation , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[128]  M. Nagarkatti,et al.  Role of Myeloid-Derived Suppressor Cells in Amelioration of Experimental Autoimmune Hepatitis Following Activation of TRPV1 Receptors by Cannabidiol , 2011, PloS one.

[129]  C. Eng,et al.  Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. , 2011, Cancer letters.

[130]  C. Osycka-Salut,et al.  Anandamide Capacitates Bull Spermatozoa through CB1 and TRPV1 Activation , 2011, PloS one.

[131]  C. Stief,et al.  Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. , 2011, The Journal of urology.

[132]  C. Limebeer,et al.  Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews , 2011, Psychopharmacology.

[133]  C. Constantinescu,et al.  Cannabinoids and the immune system: an overview. , 2010, Immunobiology.

[134]  J. Flores,et al.  Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition , 2010, Molecular Cancer.

[135]  K. Hayakawa,et al.  Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke , 2010, Pharmaceuticals.

[136]  M. Parsons,et al.  The effects of Δ9‐tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis , 2010, British journal of pharmacology.

[137]  K. Mackie,et al.  CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.

[138]  E. Choi,et al.  Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.

[139]  Hong Zhang,et al.  Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis , 2009, Inflammatory bowel diseases.

[140]  S. Dursun,et al.  Cannabidiol for the treatment of psychosis in Parkinson’s disease , 2009, Journal of psychopharmacology.

[141]  P. McGuire,et al.  Cannabis and anxiety: a critical review of the evidence , 2009, Human psychopharmacology.

[142]  R. Capasso,et al.  Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis , 2009, Journal of Molecular Medicine.

[143]  P. Stattin,et al.  A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. , 2009, European journal of cancer.

[144]  B. Sander,et al.  Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation , 2008, International journal of cancer.

[145]  L. Steardo,et al.  Effect of cannabidiol on sepsis‐induced motility disturbances in mice: involvement of CB1 receptors and fatty acid amide hydrolase , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[146]  H. Friess,et al.  Cannabinoids in pancreatic cancer: Correlation with survival and pain , 2008, International journal of cancer.

[147]  I. Raz,et al.  Cannabidiol arrests onset of autoimmune diabetes in NOD mice , 2008, Neuropharmacology.

[148]  R. Pertwee,et al.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin , 2008 .

[149]  D. Piomelli,et al.  The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat , 2008, Psychopharmacology.

[150]  R. Maldonado,et al.  Regulation of PI3K/Akt/GSK‐3 pathway by cannabinoids in the brain , 2007, Journal of neurochemistry.

[151]  M. Liao,et al.  Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. , 2007, International immunopharmacology.

[152]  X. Miao,et al.  Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. , 2006, Cancer genetics and cytogenetics.

[153]  I. Matias,et al.  Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma , 2006, Journal of Pharmacology and Experimental Therapeutics.

[154]  M. Maiuri,et al.  Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement , 2006, Neuroscience Letters.

[155]  E. Ponomarev,et al.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.

[156]  R. Mechoulam,et al.  Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease , 2005, Neurobiology of Disease.

[157]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[158]  P. Massi,et al.  Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines , 2004, Journal of Pharmacology and Experimental Therapeutics.

[159]  M. Guzmán,et al.  Cannabinoids: potential anticancer agents , 2003, Nature Reviews Cancer.

[160]  G. Bouma,et al.  The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.

[161]  M. Feldmann,et al.  The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[162]  R. Pertwee.  The central neuropharmacology of psychotropic cannabinoids. , 1988, Pharmacology & therapeutics.